FibroGen (FGEN) Surges 47% as Phase 2 Study of Pamrevlumab in IPF Meets Primary Endpoint

August 7, 2017 5:06 PM EDT Send to a Friend
FibroGen (NASDAQ: FGEN) shares are now p 46.7% amid news the company announced today positive topline results from the company’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login